DSGN · Design Therapeutics, Inc.

0001193125-26-137861

Summary

Design Therapeutics' Board appointed David Shapiro, M.D. as a Class III director effective March 31, 2026, with committee role and standard compensation under non-employee director policy.

Key takeaways

David Shapiro, M.D. appointed to Board as Class III director effective March 31, 2026, term ends at 2027 annual meeting.
Appointed to Nominating and Corporate Governance Committee.
Annual cash retainers: $40,000 for Board service, $5,000 for Nominating Committee.
Initial option grant for 60,000 shares, vesting monthly over three years.
Prorated annual option grant for 7,500 shares, vesting monthly over one year.
Entered standard indemnification agreement for directors and officers.

Full analysis

The appointment of David Shapiro, M.D. to the Board as a Class III director strengthens governance with his addition to the Nominating and Corporate Governance Committee. Compensation aligns with the company's non-employee director policy, including standard cash retainers and equity grants vesting over one to three years, signaling typical incentive structure for new directors. The standard indemnification agreement provides customary protections.